Verastem reports a 50% confirmed response rate in eight second-line pancreatic cancer patients receiving VS-7375, with a 41% rate across 22 previously treated patients at the selected 900 mg dose. The company is preparing a first-line Phase 3 study while pursuing broader development in lung and colorectal cancers.
Verastem has started TARGET-D 203, testing VS-7375 alone and in combinations for KRAS G12D metastatic colorectal cancer.
Verastem begins TARGET-D 202, testing 900 mg VS-7375 in previously treated KRAS G12D NSCLC, including a brain metastases cohort.
Find out how Verastem Oncology’s VS-7375 trial could reshape KRAS G12D pancreatic cancer treatment and what risks remain.
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.